• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

    506.70 -9.86 (-1.91%)
    Streaming Delayed Price Updated: 11:02 AM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 58,944
    Open 515.10
    Bid (Size) 506.41 (40)
    Ask (Size) 508.18 (200)
    Prev. Close 516.56
    Today's Range 502.68 - 515.10
    52wk Range 393.61 - 615.00
    Shares Outstanding 17,103,395
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗
    Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease. 
    Via The Motley Fool
    News headline image
    Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off ↗
    Rezdiffra's biggest growth opportunity may still be ahead. 
    Via The Motley Fool

    Performance

    YTD
    -14.7%
    -14.7%
    1 Month
    -5.1%
    -5.1%
    3 Month
    -3.9%
    -3.9%
    6 Month
    +0.3%
    +0.3%
    1 Year
    +14.4%
    +14.4%

    More News

    Read More
    News headline image
    Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands ↗
    Via MarketBeat
    News headline image
    Madrigal Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worries ↗
    Via Chartmill
    Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth ↗
    Via Chartmill
    Topics Earnings
    News headline image
    3 Under-the-Radar Stocks to Buy and Hold ↗
    Via The Motley Fool
    News headline image
    3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
    Via The Motley Fool
    News headline image
    Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Reports Q4 2025 Revenue Beat and Significant EPS Miss ↗
    Via Chartmill
    News headline image
    Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
    Via The Motley Fool
    News headline image
    Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Madrigal (MDGL) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
    Via The Motley Fool
    News headline image
    Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
    Via The Motley Fool
    News headline image
    This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    2 Under-the-Radar Stocks to Buy and Hold ↗
    Via The Motley Fool
    News headline image
    Madrigal (MDGL) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property
    News headline image
    Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Madrigal Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Madrigal Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Madrigal Pharmaceuticals, Inc. - Common Stock trade on?
    Madrigal Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Madrigal Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Madrigal Pharmaceuticals, Inc. - Common Stock is MDGL on the Nasdaq Stock Market
    What is the current price of Madrigal Pharmaceuticals, Inc. - Common Stock?
    The current price of Madrigal Pharmaceuticals, Inc. - Common Stock is 506.70
    When was Madrigal Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Madrigal Pharmaceuticals, Inc. - Common Stock was at 09/28/26 11:02 AM ET
    What is the market capitalization of Madrigal Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Madrigal Pharmaceuticals, Inc. - Common Stock is 8.67B
    How many shares of Madrigal Pharmaceuticals, Inc. - Common Stock are outstanding?
    Madrigal Pharmaceuticals, Inc. - Common Stock has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.